Biocartis confirms Idylla sales and patient value

September 11, 2015 News BioVox

The first half year results of Biocartis confirm a successful expansion of Idylla™, Biocartis’ fully automated molecular diagnostics system. 114 instruments (up to June 30, 2015) have been sold to various larger and smaller hospitals and distributors in and outside Europe. Idylla™ allows for faster and more accurate treatment for patients.

The recent research study of Dr. Filip Janku, MD from MD Anderson (Houston, United States) on the analytical sensitivity and specificity of the IdyllaTM BRAF Mutation Test, confirms that the IdyllaTM BRAF Mutation Test is rapid and has high concordance with other routinely used but more complex BRAF mutation–detecting tests.

Avatar photo

With a local focus and global reach, the news platform BioVox shares insights into the Benelux life sciences ecosystem with readers across the world. BioVox is an independent publisher, providing its community with quality content and first-row access to interesting breakthroughs and trends in biotech, medtech, agtech, pharma, and more. We shine a spotlight on the latest news and innovations from both our partners and community.

All posts

Subscribe to the BioVox newsletter